In accordance with the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Code of Fair Disclosure of Unpublished Price Sensitive Information & Policy for Legitimate Purpose in terms of Regulation 8 of the SEBI (Prohibition of Insider Trading) Regulations, 2015, Metropolis Healthcare has informed that the Company has provided a business update for the quarter ended December 31, 2025. This update seeks to provide an overall summary of the operating performance and demand trends witnessed during the quarter ended December 31, 2025. A detailed information update will follow once the Board of Directors approve the financial results for Q3FY26. The company delivered a strong 26% year-on-year consolidated revenue growth, driven by sustained momentum in preventive and wellness health check-ups under TruHealth, along with a strong increase in specialty testing volumes across both B2C and B2B channels. Supported by an expanded Core Diagnostics test menu for high-end specialty testing and continuous in-house innovation, the company has successfully scaled its specialty business across its pan-India network.
The above information is a part of company’s filings submitted to BSE.
